0001764013-24-000007.txt : 20240109
0001764013-24-000007.hdr.sgml : 20240109
20240109162016
ACCESSION NUMBER: 0001764013-24-000007
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240105
FILED AS OF DATE: 20240109
DATE AS OF CHANGE: 20240109
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Butchko Julia G.
CENTRAL INDEX KEY: 0001796290
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38906
FILM NUMBER: 24523491
MAIL ADDRESS:
STREET 1: 320 W 37TH STREET, 3RD FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10016
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Immunovant, Inc.
CENTRAL INDEX KEY: 0001764013
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 832771572
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0331
BUSINESS ADDRESS:
STREET 1: 320 WEST 37TH STREET
CITY: NEW YORK
STATE: NY
ZIP: 10018
BUSINESS PHONE: 917-580-3099
MAIL ADDRESS:
STREET 1: 320 WEST 37TH STREET
CITY: NEW YORK
STATE: NY
ZIP: 10018
FORMER COMPANY:
FORMER CONFORMED NAME: Health Sciences Acquisitions Corp
DATE OF NAME CHANGE: 20190108
4
1
wk-form4_1704835205.xml
FORM 4
X0508
4
2024-01-05
0
0001764013
Immunovant, Inc.
IMVT
0001796290
Butchko Julia G.
C/O IMMUNOVANT, INC.
320 W 37TH STREET, 6TH FLOOR
NEW YORK
NY
10018
0
1
0
0
Chief Development Officer
0
Common Stock
2024-01-05
4
S
0
1297
38.59
D
409963
D
On March 19, 2021, the holder was granted 54,500 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on March 23, 2021, of which 3,407 of these RSUs vested on January 1, 2024. Amounts reported herein represent shares sold by the holder solely to satisfy the holder's tax withholding obligation due in connection with the vesting and settlement of this tranche of the RSUs and do not represent a discretionary sale by the holder.
The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $38.59 - $39.27 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote to this Form 4.
/s/ Eva Renee Barnett, attorney-in-fact for Julia G. Butchko
2024-01-09